Correlation analysis of FTO protein expression with the onset of polycystic ovary syndrome and its coexistence with metabolic syndrome
10.3760/cma.j.cn101441-20250426-00206
- VernacularTitle:脂肪质量和肥胖相关蛋白表达与多囊卵巢综合征合并代谢综合征的相关性分析
- Author:
Hang LIU
1
;
Qi QIN
1
;
Liqun ZHANG
1
Author Information
1. 吉林大学第一医院妇科，长春 130021
- Publication Type:Journal Article
- Keywords:
Polycystic ovary syndrome;
FTO protein, human;
Metabolic syndrome
- From:
Chinese Journal of Reproduction and Contraception
2025;45(11):1152-1157
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To reveal the relationship between fat mass and obesity associated (FTO) protein and the occurrence of diseases in patients with polycystic ovary syndrome (PCOS) combined with metabolic syndrome (MS).Methods:A retrospective case-control study was conducted, and general clinical data and laboratory test indicators of 50 PCOS patients (PCOS group) and 54 healthy individuals (control group) were collected from December 2023 to October 2024. The PCOS group was divided into the PCOS without MS subgroup (PCOS+nMS subgroup, n=25) and the PCOS with MS subgroup (PCOS+MS subgroup, n=25) based on whether MS was present or not. The expression level of serum FTO protein was detected by enzyme-linked immunosorbent assay method. The clinical data and metabolic characteristics of PCOS patients were analyzed, as well as the correlation between serum FTO protein level and the occurrence of PCOS with MS. Receiver operating characteristic (ROC) curves were drew to analyze the predictive ability of serum FTO protein level for PCOS combined MS, and the correlation between serum FTO protein level and metabolic status of PCOS patients was evaluated through logistic regression model. Results:The level of serum FTO protein in the PCOS group [57.42 (45.87, 68.53) μg/L], and PCOS+nMS subgroup [48.41 (37.84, 64.30) μg/L] was all significantly higher than that in the control [45.70 (36.41, 52.86) μg/L, P<0.001; adjusted P=0.016]. The expression level of serum FTO protein in PCOS+MS subgroup [60.31 (50.99, 72.28) μg/L] was significantly higher than that in PCOS+nMS subgroup (adjusted P=0.013) and the control (adjusted P<0.001). The serum FTO protein expression level in the PCOS group was significantly positively correlated with body mass index, waist circumference, systolic blood pressure,diastolic blood pressure, low density lipoprotein cholesterol, homeostasis model to assess insulin resistance index (all P<0.05). The expression level of serum FTO protein had a certain predictive value for PCOS, with an area under the curve (AUC) value of 0.725 (95% CI: 0.627-0.824) and a better predictive value for the occurrence of MS in PCOS, with an AUC value of 0.869 (95% CI: 0.762-0.976) as shown by the ROC curve. Multivariate logistic regression analysis indicated that in PCOS patients, the expression level of serum FTO protein had a significant positive effect on the coexistence of MS, ( OR=1.092,95% CI: 1.010-1.180, P=0.026). Conclusion:PCOS patients have higher serum FTO protein levels than healthy women, and PCOS patients with MS have higher serum FTO protein levels than those without MS. The serum FTO protein level has a good predictive value for the occurrence of PCOS and PCOS complicated with MS, and is an independent risk factor for the occurrence of MS in PCOS.
